Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Re-CHARM: Semaglutide and Exercise in Type 2 Diabetes
NCT07065383Recruiting
- Sponsor
- University of Aberdeen
- Start
- Aug 2025
- Primary completion
- Jul 2028
- Modality
- Peptides, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Randomised, open-label trial of semaglutide in type 2 diabetes mellitus (T2DM) (2 arms), sponsored by University of Aberdeen. Primary endpoint: 1H-magnetic resonance spectroscopy at 12 weeks. Started Aug 2025; status: recruiting.
02
Drugs
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT07065383.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07065383.